mizagliflozin
Small moleculeexperimental
Clinical trial activity
8 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
7
Phase 3
0
Phase 4
0
Earliest trial started May 14, 2012 (NCT01600001)
Timeline
Indications
Mechanism of action
- SGLT1 proteinINHIBITOR
SLC5A1 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
Cc1cc(OCCCNCC(C)(C)C(N)=O)ccc1Cc1c(O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)n[nH]c1C(C)C- Mol. weight
- 564.68 g/mol
- Lipinski Ro5
- 2 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL5314923 ↗
Also known as
- kwa-0711
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05721729 | Phase 2 | Jun 23, 2023 | Vogenx, Inc. |
| NCT05541939 | Phase 2 | Sep 13, 2022 | Vogenx, Inc. |
| NCT02434835 | Phase 1 | Apr 21, 2015 | Kissei Pharmaceuticals |
| NCT02343978 | Phase 2 | Dec 26, 2014 | Kissei Pharmaceuticals |
| NCT02281630 | Phase 2 | Oct 15, 2014 | Kissei Pharmaceuticals |
| NCT01938196 | Phase 2 | Aug 27, 2013 | Kissei Pharmaceuticals |
| NCT01937663 | Phase 2 | Aug 27, 2013 | Kissei Pharmaceuticals |
| NCT01600001 | Phase 2 | May 14, 2012 | Kissei Pharmaceuticals |
Showing 8 of 8 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Kissei Pharmaceuticals | For profit | 6 | 6 | 2 | 2012 |
| Vogenx, Inc. | For profit | 2 | 2 | 1 | 2022 |
2 organizations
Page 1 / 1